Top

Journal of Gastrointestinal Surgery

Published in:

Open Access 01-06-2018 | Original Article

Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis

Authors: Chaobin He, Yu Zhang, Xiaojun Lin

Published in: Journal of Gastrointestinal Surgery | Issue 6/2018

Abstract

Background

In analyzing cancer patient survival data, the problem of competing risks is often ignored. This study used a competing risk approach to evaluate the efficacy of recombinant human type-5 adenovirus (H101) in patients with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE).

Methods

In this retrospective study, 476 patients were included. The cumulative probabilities of cancer-specific mortalities were analyzed by the Kaplan-Meier (KM) method and a competing risk model. Competing risk regression was used to assess the predictive factors for cumulative cancer-specific mortalities.

Results

Two hundred thirty-eight HCC patients received combination TACE and H101 therapy, and another 238 HCC patients received TACE therapy alone. For patients in the TACE with H101 group, estimated 1-, 2-, and 3-year overall survival (OS) rates were 61.0, 40.0, and 31.5%, respectively, while for patients in the TACE group, the estimated 1-, 2-, and 3-year OS rates were 55.0, 33.4, and 22.3%, respectively. The 1-, 2-, and 3-year cancer-specific mortality rates for patients in the TACE with H101 group vs. the TACE group were 37.3 vs. 42.0%, 55.7 vs. 63.5%, and 61.9 vs. 74.7%, respectively. Multivariate competing risk analysis established that a combination of TACE and H101 therapy was an independent factor in decreasing cancer-specific mortality.

Conclusions

Compared with TACE therapy, patients who were diagnosed with unresectable HCC treated with combined TACE and H101 therapy had increased OS and decreased cancer-specific mortality. The survival benefit was more obvious in patients with elevated AFP, absence of metastasis, single tumor, enlarged tumor, and HBsAg-positivity.

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: a cancer journal for clinicians. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.CrossRef

Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World journal of gastroenterology. 2014;20(15):4115–27. https://doi.org/10.3748/wjg.v20.i15.4115.CrossRefPubMedPubMedCentral

Zhang J, Zhou ZG, Huang ZX, Yang KL, Chen JC, Chen JB et al. Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. Chinese journal of cancer. 2016;35:25. https://doi.org/10.1186/s40880-016-0088-0.CrossRefPubMedPubMedCentral

Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134(7):1908–16. https://doi.org/10.1053/j.gastro.2008.02.091.CrossRefPubMed

Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md). 2011;53(3):1020–2. https://doi.org/10.1002/hep.24199.CrossRef

Okazaki M, Yamasaki S, Ono H, Higashihara H, Koganemaru F, Kimura S et al. Chemoembolotherapy for recurrent hepatocellular carcinoma in the residual liver after hepatectomy. Hepato-gastroenterology. 1993;40(4):320–3.PubMed

Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (Baltimore, Md). 2003;37(2):429–42. https://doi.org/10.1053/jhep.2003.50047.CrossRef

Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S179–88.CrossRefPubMed

Yoshimitsu K. Transarterial chemoembolization using iodized oil for unresectable hepatocellular carcinoma: perspective from multistep hepatocarcinogenesis. Hepatic medicine : evidence and research. 2014;6:89–94. https://doi.org/10.2147/hmer.s31440.CrossRef

10.

Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. Journal of hepatology. 2009;50(3):604–20. https://doi.org/10.1016/j.jhep.2008.12.011.CrossRefPubMed

11.

Lubienski A, Simon M, Lubienski K, Gellissen J, Hoffmann RT, Jakobs TF et al. [Update on chemoinfusion and chemoembolization treatments]. Der Radiologe. 2007;47(12):1097–106, 108. https://doi.org/10.1007/s00117-007-1587-4.CrossRefPubMed

12.

Bishop JM. The molecular genetics of cancer. Science (New York, NY). 1987;235(4786):305–11.CrossRef

13.

Cowell JK. Tumour suppressor genes. Annals of oncology : official journal of the European Society for Medical Oncology. 1992;3(9):693–8.CrossRef

14.

Honda K, Sbisa E, Tullo A, Papeo PA, Saccone C, Poole S et al. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. British journal of cancer. 1998;77(5):776–82.CrossRefPubMedPubMedCentral

15.

Kasuya H, Takeda S, Shimoyama S, Shikano T, Nomura N, Kanazumi N et al. Oncolytic virus therapy--foreword. Current cancer drug targets. 2007;7(2):123–5.CrossRefPubMed

16.

Guse K, Hemminki A. Cancer gene therapy with oncolytic adenoviruses. Journal of BUON : official journal of the Balkan Union of Oncology. 2009;14 Suppl 1:S7–15.

17.

Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Molecular therapy : the journal of the American Society of Gene Therapy. 2010;18(2):243–50. https://doi.org/10.1038/mt.2009.266.CrossRef

18.

Kirn D, Hermiston T, McCormick F. ONYX-015: clinical data are encouraging. Nature medicine. 1998;4(12):1341–2. https://doi.org/10.1038/3902.CrossRefPubMed

19.

Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World journal of gastroenterology. 2004;10(24):3634–8.CrossRefPubMedPubMedCentral

20.

Herbst RS, Heymach JV, Lippman SM. Lung cancer. The New England journal of medicine. 2008;359(13):1367–80. https://doi.org/10.1056/NEJMra0802714.CrossRefPubMed

21.

Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer research. 2002;62(21):6070–9.PubMed

22.

Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in medicine. 1999;18(6):695–706.CrossRefPubMed

23.

Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Statistics in medicine. 2007;26(11):2389–430. https://doi.org/10.1002/sim.2712.CrossRefPubMed

24.

Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data, vol 360. Hoboken: John Wiley & Sons; 2011.

25.

Zhang J, Peng H, Chen L, Li WF, Mao YP, Liu LZ et al. Decreased Overall and Cancer-Specific Mortality with Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Treated by Intensity-modulated Radiotherapy: Multivariate Competing Risk Analysis. Journal of Cancer. 2017;8(13):2587–94. https://doi.org/10.7150/jca.20081.CrossRefPubMedPubMedCentral

26.

Chang YH, Li WH, Chang Y, Peng CW, Cheng CH, Chang WP et al. Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis. BMC cancer. 2016;16:235. https://doi.org/10.1186/s12885-016-2279-0.CrossRefPubMedPubMedCentral

27.

Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109(9):1763–8. https://doi.org/10.1002/cncr.22600.CrossRefPubMed

28.

Hsieh KP, Chen LC, Cheung KL, Yang YH. A competing risk analysis of hormone therapy interruption in Asian women with breast cancer. Pharmacoepidemiology and drug safety. 2015;24(3):301–9. https://doi.org/10.1002/pds.3733.CrossRefPubMed

29.

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. Journal of hepatology. 2001;35(3):421–30.CrossRefPubMed

30.

Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Annals of surgical oncology. 2011;18(2):413–20. https://doi.org/10.1245/s10434-010-1321-8.CrossRefPubMed

31.

Lin XJ, Li QJ, Lao XM, Yang H, Li SP. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC). BMC cancer. 2015;15:707. https://doi.org/10.1186/s12885-015-1715-x.CrossRefPubMedPubMedCentral

32.

Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of statistics. 1988:1141–54.

33.

Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American statistical association. 1999;94(446):496–509.CrossRef

34.

He CB, Lao XM, Lin XJ. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. Chinese journal of cancer. 2017;36(1):59. https://doi.org/10.1186/s40880-017-0227-2.CrossRefPubMedPubMedCentral

35.

Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. American journal of epidemiology. 2009;170(2):244–56. https://doi.org/10.1093/aje/kwp107.CrossRefPubMedPubMedCentral

36.

Tice JA, Miglioretti DL, Li CS, Vachon CM, Gard CC, Kerlikowske K. Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(28):3137–43. https://doi.org/10.1200/jco.2015.60.8869.CrossRef

37.

Vilaprinyo E, Gispert R, Martinez-Alonso M, Carles M, Pla R, Espinas JA et al. Competing risks to breast cancer mortality in Catalonia. BMC cancer. 2008;8:331. https://doi.org/10.1186/1471-2407-8-331.CrossRefPubMedPubMedCentral

38.

Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. British journal of cancer. 2004;91(7):1229–35. https://doi.org/10.1038/sj.bjc.6602102.CrossRefPubMedPubMedCentral

39.

Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (New York, NY). 1996;274(5286):373–6.CrossRef

40.

Wang Y, Zheng WL, Ma WL. Lobaplatin inhibits the proliferation of hepatollular carcinoma through p53 apoptosis axis. Hepatitis Monthly. 2012;12(10 hcc):e6024. https://doi.org/10.5812/hepatmon.6024.CrossRefPubMedPubMedCentral

41.

Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Seminars in liver disease. 2010;30(1):3–16. https://doi.org/10.1055/s-0030-1247128.CrossRefPubMed

42.

Matsuda Y, Ichida T. Impact of hepatitis B virus X protein on the DNA damage response during hepatocarcinogenesis. Medical molecular morphology. 2009;42(3):138–42. https://doi.org/10.1007/s00795-009-0457-8.CrossRefPubMed

43.

Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver. 2013;33(4):595–604. https://doi.org/10.1111/liv.12112.CrossRef

44.

Zhou ZG, Zheng XR, Zhou Q, Shi M, Zhang YJ, Guo RP et al. Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. Chinese journal of cancer. 2015;34(5):205–16. https://doi.org/10.1186/s40880-015-0017-7.PubMedCrossRef

45.

Zhang N, Gu J, Yin L, Wu J, Du MY, Ding K et al. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database. Oncotarget. 2016;7(49):81389–401. https://doi.org/10.18632/oncotarget.13232.PubMedPubMedCentralCrossRef

46.

Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer research. 1994;54(18):4855–78.PubMed

47.

Hsia CC, Nakashima Y, Thorgeirsson SS, Harris CC, Minemura M, Momosaki S et al. Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma. Oncology reports. 2000;7(2):353–6.PubMed

48.

Shen A, Liu S, Yu W, Deng H, Li Q. p53 gene therapy-based transarterial chemoembolization for unresectable hepatocellular carcinoma: A prospective cohort study. Journal of gastroenterology and hepatology. 2015;30(11):1651–6. https://doi.org/10.1111/jgh.13009.CrossRefPubMed

49.

El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology (Baltimore, Md). 1998;27(6):1554–62. https://doi.org/10.1002/hep.510270613.CrossRef

Title: Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis
Authors: Chaobin He
Yu Zhang
Xiaojun Lin
Publication date: 01-06-2018
Publisher: Springer US
Published in: Journal of Gastrointestinal Surgery / Issue 6/2018
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-018-3703-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Inflammatory Myofibroblastic Tumor of the Liver: Challenges in the Preoperative Diagnosis and Treatment

Propensity Score-Matched Analysis of Clinical and Financial Outcomes After Robotic and Laparoscopic Colorectal Resection

Gastric Calcifying Fibrous Tumor Manifesting as a Subepithelial Tumor

The Influence of Screening on Outcomes of Clinically Locally Advanced Rectal Cancer

Unplanned Robotic-Assisted Conversion-to-Open Colorectal Surgery is Associated with Adverse Outcomes

Diffuse Cystic Malformation with Early Gastric Cancer